Jun. 6 at 2:52 PM
$KYTX “Miv-cel is delivering a depth of B-cell depletion that we have not seen with existing therapies in patients with difficult-to-treat rheumatoid arthritis,” said David Simon, M.D., Head of the Clinical Trial Unit in the Department of Rheumatology and Clinical Immunology at Charité, University of Berlin and Principal Investigator of the COMPARE trial. “Notably, miv-cel clears disease-driving B cells from key tissues, such as bone marrow and inflamed joints. When peripheral B cells return, they predominantly show a naïve and transitional phenotype, and ACPA titers continue to decline in a majority of patients, supporting the potential for a durable immune reset following a single dose of miv-cel.”
Based on the Phase 1 findings, the Phase 2 portion of the COMPARE trial has been initiated and is fully enrolled. This trial compares B-cell depletion with miv-cel versus rituximab in patients with active ACPA-positive, treatment refractory RA with moderate to high disease activity.
